When is change in the Shuttle Walk Test clinically meaningful

Responsiveness of the Modified Incremental Shuttle Walk Test in Cardiac Rehabilitation - Global Rating Scale Anchor in the Incremental Shuttle Test

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58150

Enrollment

300

Registered

2025-11-13

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease (CAD), Myocardial infarction, Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI), Ischemic heart disease blockages in the heart’s blood vessels, heart attack, stent procedure to open a heart artery, Heart disease caused by reduced blood flow to the heart

Interventions

We are studying the Modified Incremental Shuttle Walk Test. This is a walking test in which a patient walks back and forth between two cones at an increasingly faster pace.

Eligibility

Inclusion criteria

Inclusion criteria: Participation in and completion of the cardiac rehabilitation program at Zuyderland, with a minimum of six rehabilitation sessions.Adult men and women aged >18 years.Participants who can understand and speak Dutch or English in order to take part in communication and evaluation during the study.

Exclusion criteria

Exclusion criteria: Heart failureParticipants who are deemed unsuitable by the physiotherapist to perform the ISWT.Stop criteria for the test based on comorbidity-related symptoms or risks.

Design outcomes

Primary

Measure	Time frame
GRS MISWT, start en end of rehabilitation	—

Secondary

Measure	Time frame
Reason for cardiac rehabilitationPatient characteristicsAge (at time of inclusion)Biological sex (male/female)Relevant medical historyAtrial fibrillation (de novo / paroxysmal / persistent / permanent)Coronary artery disease (1VD / 2VD / 3VD / left main)Valve disease (mild / moderate / severe)Stroke / TIAPeripheral vascular diseaseCOPD (GOLD I / II / III / IV)AnemiaMedication affecting exercise toleranceBeta-blockerStatinErgometrics resultsBlood pressure at start (systolic / diastolic)Blood pressure at peak exercise (systolic / diastolic)Heart rate at peak exercise (bpm)MET scoreReason for stopping (angina / dyspnea / fatigue / muscle weakness)Ergometry conclusion (positive or significant ECG abnormalities / non-significant / inconclusive)AnthropometricsHeightWeightMISWT resultsMISWT at start of cardiac rehabilitation (meters)MISWT at end of cardiac rehabilitation (meters)METsMETs at start of cardiac rehabilitationMETs at end of cardiac rehabilitationRehabilitation programDuration of physiotherapy (weeks)Categorization of exercise capacity (low / medium / high)Use of tele-rehabilitation (yes/no)Short or long program	—

Measure

Time frame

Reason for cardiac rehabilitationPatient characteristicsAge (at time of inclusion)Biological sex (male/female)Relevant medical historyAtrial fibrillation (de novo / paroxysmal / persistent / permanent)Coronary artery disease (1VD / 2VD / 3VD / left main)Valve disease (mild / moderate / severe)Stroke / TIAPeripheral vascular diseaseCOPD (GOLD I / II / III / IV)AnemiaMedication affecting exercise toleranceBeta-blockerStatinErgometrics resultsBlood pressure at start (systolic / diastolic)Blood pressure at peak exercise (systolic / diastolic)Heart rate at peak exercise (bpm)MET scoreReason for stopping (angina / dyspnea / fatigue / muscle weakness)Ergometry conclusion (positive or significant ECG abnormalities / non-significant / inconclusive)AnthropometricsHeightWeightMISWT resultsMISWT at start of cardiac rehabilitation (meters)MISWT at end of cardiac rehabilitation (meters)METsMETs at start of cardiac rehabilitationMETs at end of cardiac rehabilitationRehabilitation programDuration of physiotherapy (weeks)Categorization of exercise capacity (low / medium / high)Use of tele-rehabilitation (yes/no)Short or long program

—

Countries

Netherlands

Contacts

Public ContactF.W.W. Heijkens-Verberkt

Zuyderland

f.verberkt@zuyderland.nl06-57735896

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)